Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b safety, PK, PD, and immunogenicity study of cetrelimab ± erdafitinib in Japanese patients with advanced solid cancers
jRCT2080223997Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of cetrelimab in Nonhematologic neoplasms and cancer (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of cetrelimab as monotherapy and in combination with erdafitinib, Pharmacokinetics of cetrelimab and 2 more. Started Aug 2018; status: completed.
02
Drugs
cetrelimab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2080223997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223997.